Safety Study Of SNX-5422 To Treat Solid Tumor Cancers And Lymphomas

NCT00647764 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

32

Enrollment

INDUSTRY

Sponsor class

Conditions

Solid Tumor Malignancy
Lymphoid Malignancy (Lymphoma and CLL)
Leukemia
Lymphoma

Interventions

DRUG: SNX-5422 Mesylate Hsp90 inhibitor

Sponsor

Esanex Inc.

Collaborators

[object Object]